International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report) was the target of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totaling 808 shares, a decrease of 89.7% from the August 15th total of 7,881 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 92,036 shares, the short-interest ratio is currently 0.0 days.
International Stem Cell Price Performance
Shares of ISCO stock traded down $0.01 during trading hours on Thursday, reaching $0.36. The stock had a trading volume of 28,587 shares, compared to its average volume of 29,057. International Stem Cell has a twelve month low of $0.12 and a twelve month high of $0.54. The firm has a 50-day simple moving average of $0.31 and a 200-day simple moving average of $0.22. The firm has a market capitalization of $2.88 million and a PE ratio of -4.50.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last posted its earnings results on Thursday, August 13th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $2.67 million for the quarter.
International Stem Cell Company Profile
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
See Also
- Five stocks we like better than International Stem Cell
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
